DUAL ANTIPLATELET THERAPY FOR PREVENTION OF COMPLICATIONS IN PERIPHERAL ARTERY DISEASE
Abstract: Aims and Objectives: Peripheral Artery Disease is a frequent pathology, leading to severe cardiovascular and limb complications. The use of dual antiplatelet therapy, tough potentially beneficial for these patients, is still controversial and needs more attentive consideration. This review analyses its use in both mild and more severe stages of the disease, aiming to reveal its safety and efficacy through the meticulous analysis of the current research available on the topic. Material and Methods: After and advanced search on PubMed and a thorough selection of the retrieved results, 12 articles were included. Results and Interpretation: Dual antiplatelet therapy with Aspirin and Clopidogrel fails to prove its efficacy when used in patients with asymptomatic or mild peripheral artery disease, with its use being much more beneficial for patients with advanced forms of it. Similar results describe the use of Ticagrelor in addition to Aspirin. Vorapaxar is a novel medication potentially beneficial as part of dual antiplatelet therapy. In patients who underwent endovascular revascularization, 12 months of dual antiplatelet therapy reduce mortality compared to 6 months only. For patients who underwent surgical revascularization, dual antiplatelet therapy fails to provide significant improvements compared to Aspirin only. Conclusions: Dual antiplatelet therapy has a positive impact for patients suffering from moderate or severe peripheral artery disease and also in patients treated endovascularly for its complications. Less satisfactory findings were found for patients undergoing surgical revascularization. However, there is need for more research in the field.
 M. A. Hussain, M. Al-Omran, M. A. Creager, S. S. Anand, S. Verma, and D. L. Bhatt, “Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances,” Journal of the American College of Cardiology, vol. 71, no. 21. Elsevier USA, pp. 2450–2467, May 29, 2018, doi: 10.1016/j.jacc.2018.03.483.
 N. Govsyeyev, M. R. Nehler, W. R. Hiatt, and M. P. Bonaca, “Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD,” Current Cardiology Reports, vol. 22, no. 3. Springer, Mar. 01, 2020, doi: 10.1007/s11886-020-1264-z.
 A. C. Beiswenger, A. Jo, K. Harth, N. H. Kumins, M. H. Shishehbor, and V. S. Kashyap, “A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease,” Journal of Vascular Surgery, vol. 67, no. 6. Mosby Inc., pp. 1922-1932.e6, Jun. 01, 2018, doi: 10.1016/j.jvs.2018.02.047.
 M. D. Gerhard-Herman et al., “2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” J. Am. Coll. Cardiol., vol. 69, no. 11, pp. 1465–1508, 2017, doi: 10.1016/j.jacc.2016.11.008.
 E. J. Armstrong et al., “Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease,” J. Vasc. Surg., vol. 62, no. 1, pp. 157-165.e1, 2015, doi: 10.1016/j.jvs.2015.01.051.
 E. Kaplovitch, L. Rannelli, and S. S. Anand, “Antithrombotics in stable peripheral artery disease,” Vascular Medicine (United Kingdom), vol. 24, no. 2. SAGE Publications Ltd, pp. 132–140, Apr. 01, 2019, doi: 10.1177/1358863X18820123.
 A. Majithia and D. L. Bhatt, “Novel Antiplatelet Therapies for Atherothrombotic Diseases,” Arteriosclerosis, thrombosis, and vascular biology, vol. 39, no. 4. NLM (Medline), pp. 546–557, Apr. 01, 2019, doi: 10.1161/ATVBAHA.118.310955.
 R. J. Gryka, L. F. Buckley, and S. M. Anderson, “Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease,” Drugs R D, vol. 17, no. 1, pp. 65–72, 2017, doi: 10.1007/s40268-016-0158-4.
 A. Franzone et al., “Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY randomized clinical trial,” JAMA Cardiol., vol. 1, no. 7, pp. 795–803, 2016, doi: 10.1001/jamacardio.2016.2811.
 K. Sarode et al., “Comparison of dual-antiplatelet therapy durations after endovascular revascularization of infrainguinal arteries,” Ann. Vasc. Surg., vol. 29, no. 6, pp. 1235–1244, 2015, doi: 10.1016/j.avsg.2015.03.040.
 S. Arya, S. L. Zettervall, K. H. J. Ultee, and M. L. Schermerhorn, “Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization,” J. Vasc. Surg., vol. 64, no. 6, pp. 1633-1644.e1, 2016, doi: 10.1016/j.jvs.2016.05.098.